Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids.
暂无分享,去创建一个
D. Ichikawa | E. Otsuji | A. Shiozaki | S. Komatsu | K. Okamoto | H. Konishi | H. Ikoma | R. Morimura | T. Ohashi | T. Arita | T. Imamura | T. Kawaguchi | M. Miyamae | W. Okajima | Mahito Miyamae | Takuma Ohashi | Wataru Okajima | Taisuke Imamura
[1] Y. Miao,et al. Plasma miRNAs Effectively Distinguish Patients With Pancreatic Cancer From Controls: A Multicenter Study , 2016, Annals of surgery.
[2] H. Ueno,et al. Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer , 2015, Scientific Reports.
[3] D. Ichikawa,et al. Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer , 2015, British Journal of Cancer.
[4] N. Malats,et al. Circulating tumor cells (CTC) and KRAS mutant circulating free DNA (cfDNA) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer , 2015, BMC Cancer.
[5] Lei Zhao,et al. Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers , 2015, Oncotarget.
[6] Katherine Van Loon,et al. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. , 2015, Cancer discovery.
[7] D. Ichikawa,et al. Malignant potential in pancreatic neoplasm: new insights provided by circulating mir-223 in plasma , 2015 .
[8] V. Konda,et al. Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound , 2015, Gastroenterology.
[9] K. Lillemoe,et al. Circulating Epithelial Cells in Patients with Pancreatic Lesions: Clinical and Pathologic Findings. , 2015, Journal of the American College of Surgeons.
[10] D. Coppola,et al. Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas , 2015, Cancer Prevention Research.
[11] R. Scharpf,et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients , 2015, Nature Communications.
[12] K. Nouso,et al. Detection of K‐ras gene mutation by liquid biopsy in patients with pancreatic cancer , 2015, Cancer.
[13] M. Büchler,et al. Combined evaluation of a panel of protein and miRNA serum‐exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity , 2015, International journal of cancer.
[14] K. Lillemoe,et al. Circulating Tumor Cells Found in Patients With Localized and Advanced Pancreatic Cancer , 2015, Pancreas.
[15] Lenka Záveská Drábková,et al. Evaluation of Cell-Free Urine microRNAs Expression for the Use in Diagnosis of Ovarian and Endometrial Cancers. A Pilot Study , 2015, Pathology & Oncology Research.
[16] Rui Yang,et al. Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer , 2015, Tumor Biology.
[17] Gerta Rücker,et al. Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker , 2015, BMC Cancer.
[18] Fang Liu,et al. SELEX Aptamer Used as a Probe to Detect Circulating Tumor Cells in Peripheral Blood of Pancreatic Cancer Patients , 2015, PloS one.
[19] Donghong Zhang,et al. Patterns of circulating tumor cells identified by CEP8, CK and CD45 in pancreatic cancer , 2015, International journal of cancer.
[20] Motohiro Kojima,et al. MicroRNA Markers for the Diagnosis of Pancreatic and Biliary-Tract Cancers , 2015, PloS one.
[21] R. Pandey,et al. High Levels of Cell-Free Circulating Nucleic Acids in Pancreatic Cancer are Associated With Vascular Encasement, Metastasis and Poor Survival , 2015, Cancer investigation.
[22] W. Yu,et al. Increased expression of the lncRNA PVT1 is associated with poor prognosis in pancreatic cancer patients. , 2015, Minerva medica.
[23] M. Braga,et al. Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer , 2015, Tumor Biology.
[24] W. Guo,et al. Co-amplification at lower denaturation-temperature PCR combined with unlabled-probe high-resolution melting to detect KRAS codon 12 and 13 mutations in plasma-circulating DNA of pancreatic adenocarcinoma cases. , 2015, Asian Pacific journal of cancer prevention : APJCP.
[25] E. Kebebew,et al. Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors. , 2015, Molecular endocrinology.
[26] V. Bobek,et al. Circulating tumor cells in pancreatic cancer patients: enrichment and cultivation. , 2014, World journal of gastroenterology.
[27] Wei Gao,et al. Long noncoding RNA HULC is a novel biomarker of poor prognosis in patients with pancreatic cancer , 2014, Medical Oncology.
[28] N. Tanaka,et al. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer , 2014, International journal of oncology.
[29] Qiulan Chen,et al. Circulating microRNA-182 in plasma and its potential diagnostic and prognostic value for pancreatic cancer , 2014, Medical Oncology.
[30] Jie Hong,et al. A novel long non-coding RNA ENST00000480739 suppresses tumour cell invasion by regulating OS-9 and HIF-1α in pancreatic ductal adenocarcinoma , 2014, British Journal of Cancer.
[31] W. Liu,et al. Long non-coding RNAs expressed in pancreatic ductal adenocarcinoma and lncRNA BC008363 an independent prognostic factor in PDAC. , 2014, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[32] K. Strauch,et al. MicroRNA-196a and -196b as Potential Biomarkers for the Early Detection of Familial Pancreatic Cancer , 2014, Translational oncology.
[33] Klaus Pantel,et al. [The circulating tumor cells: liquid biopsy of cancer]. , 2014, Klinicheskaia laboratornaia diagnostika.
[34] B. Ramaswamy,et al. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients , 2014, Breast Cancer Research.
[35] Timothy B Lannin,et al. Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions. , 2014, Gastroenterology.
[36] G. A. Ganepola,et al. Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer. , 2014, World journal of gastrointestinal oncology.
[37] Thomas J George,et al. Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip. , 2014, Lab on a chip.
[38] C. Peng,et al. Downregulation of gas5 increases pancreatic cancer cell proliferation by regulating CDK6 , 2013, Cell and Tissue Research.
[39] S. Soper,et al. Modular microsystem for the isolation, enumeration, and phenotyping of circulating tumor cells in patients with pancreatic cancer. , 2013, Analytical chemistry.
[40] Ri-sheng Que,et al. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma , 2013, World Journal of Surgical Oncology.
[41] E. Fishman,et al. Recent progress in pancreatic cancer , 2013, CA: a cancer journal for clinicians.
[42] F. Nicolantonio,et al. Liquid biopsy: monitoring cancer-genetics in the blood , 2013, Nature Reviews Clinical Oncology.
[43] F. Bidard,et al. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[44] Min Shi,et al. Diagnostic and biological significance of microRNA-192 in pancreatic ductal adenocarcinoma. , 2013, Oncology reports.
[45] Kun Wang,et al. The serum miR‐21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR‐21 expression confers chemoresistance by targeting FasL , 2013, Molecular oncology.
[46] R. Hruban,et al. MicroRNA Array Analysis Finds Elevated Serum miR-1290 Accurately Distinguishes Patients with Low-Stage Pancreatic Cancer from Healthy and Disease Controls , 2013, Clinical Cancer Research.
[47] S. Bojesen,et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. , 2013, JAMA.
[48] N. Rosenfeld,et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.
[49] J. Kench,et al. Classification, morphology and molecular pathology of premalignant lesions of the pancreas , 2013, Pathology.
[50] Carlos Caldas,et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.
[51] D. Jin,et al. Combined Serum CA19-9 and miR-27a-3p in Peripheral Blood Mononuclear Cells to Diagnose Pancreatic Cancer , 2013, Cancer Prevention Research.
[52] D. Ichikawa,et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer , 2013, British Journal of Cancer.
[53] C. Andersen,et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma , 2013, International journal of cancer.
[54] S. Knudsen,et al. Cell-Free Plasma MicroRNA in Pancreatic Ductal Adenocarcinoma and Disease Controls , 2012, Pancreas.
[55] Y. Gong,et al. Combination of plasma microRNAs with serum CA19‐9 for early detection of pancreatic cancer , 2012, International journal of cancer.
[56] N. Morgenthaler,et al. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire , 2012, International journal of oncology.
[57] ENCODEConsortium,et al. An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.
[58] Enzo Medico,et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.
[59] Johannes G. Reiter,et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.
[60] I. Tinhofer,et al. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition , 2012, BMC Cancer.
[61] S. Safe,et al. HOTAIR IS A NEGATIVE PROGNOSTIC FACTOR AND EXHIBITS PRO-ONCOGENIC ACTIVITY IN PANCREATIC CANCER , 2012, Oncogene.
[62] R. Datar,et al. Progress in circulating tumor cell capture and analysis: implications for cancer management , 2012, Expert review of molecular diagnostics.
[63] Steven Gray,et al. Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. , 2012, Lung cancer.
[64] Xi Chen,et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. , 2012, Clinical chemistry.
[65] Terry Hyslop,et al. Clinical Significance of Serum COL6A3 in Pancreatic Ductal Adenocarcinoma , 2013, Journal of Gastrointestinal Surgery.
[66] Sepp Kaul,et al. Multimarker Gene Analysis of Circulating Tumor Cells in Pancreatic Cancer Patients: A Feasibility Study , 2012, Oncology.
[67] T. Itoi,et al. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study) , 2012, Cancer Chemotherapy and Pharmacology.
[68] L Khoja,et al. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker , 2011, British Journal of Cancer.
[69] M. Bouvet,et al. Marker expression in circulating cancer cells of pancreatic cancer patients. , 2011, The Journal of surgical research.
[70] Sergio Verjovski-Almeida,et al. Long noncoding intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer , 2011, Molecular Cancer.
[71] D. Ichikawa,et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer , 2011, British Journal of Cancer.
[72] Jaap M J den Toonder,et al. Circulating tumor cell isolation and diagnostics: toward routine clinical use. , 2011, Cancer research.
[73] J. Marshall,et al. Tissue and Serum microRNAs in the KrasG12D Transgenic Animal Model and in Patients with Pancreatic Cancer , 2011, PloS one.
[74] Klaus Pantel,et al. Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.
[75] E. Kroh,et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma , 2011, Proceedings of the National Academy of Sciences.
[76] Y. Gong,et al. Detection of Differentially Expressed microRNAs in Serum of Pancreatic Ductal Adenocarcinoma Patients: miR-196a Could Be a Potential Marker for Poor Prognosis , 2011, Digestive Diseases and Sciences.
[77] A. Iafrate,et al. Aberrant Overexpression of Satellite Repeats in Pancreatic and Other Epithelial Cancers , 2011, Science.
[78] M. Nowak,et al. Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.
[79] K. Isselbacher,et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip , 2010, Proceedings of the National Academy of Sciences.
[80] Kimberly Walter,et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. , 2010, Cancer research.
[81] Z. Meng,et al. K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[82] Quynh-Thu Le,et al. Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. , 2010, Translational oncology.
[83] R. Abrams,et al. Differential methylation of cell‐free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis , 2010, Cancer.
[84] Y. Matsuki,et al. Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells*♦ , 2010, The Journal of Biological Chemistry.
[85] M. Moore,et al. Advanced pancreatic carcinoma: current treatment and future challenges , 2010, Nature Reviews Clinical Oncology.
[86] Ann M. Killary,et al. MicroRNAs in Plasma of Pancreatic Ductal Adenocarcinoma Patients as Novel Blood-Based Biomarkers of Disease , 2009, Cancer Prevention Research.
[87] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[88] D. Scholtens,et al. Methylation profile of circulating plasma DNA in patients with pancreatic cancer , 2009, Journal of surgical oncology.
[89] Daniel B. Martin,et al. Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.
[90] M. Neri,et al. K-ras mutations in circulating DNA from pancreatic and lung cancers: bridging methodology for a common validation of the molecular diagnosis value. , 2008, Pancreas.
[91] J. Neoptolemos,et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses , 2008, British Journal of Cancer.
[92] M. Sanz-Casla,et al. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[93] F. Itokawa,et al. Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. , 2008, Journal of hepato-biliary-pancreatic surgery.
[94] R. Labianca,et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer , 2008, BMC Cancer.
[95] Glenn Heller,et al. Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer , 2007, Clinical Cancer Research.
[96] J. Lötvall,et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.
[97] H. Scher,et al. Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer , 2007, Clinical Cancer Research.
[98] Brigitte Rack,et al. Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System , 2007, Clinical Cancer Research.
[99] J. Thiery,et al. Detection of disseminated pancreatic cells by amplification of cytokeratin-19 with quantitative RT-PCR in blood, bone marrow and peritoneal lavage of pancreatic carcinoma patients. , 2007, World journal of gastroenterology.
[100] S. Aliño,et al. Real‐Time Quantification of Human Telomerase Reverse Transcriptase mRNA in the Plasma of Patients with Prostate Cancer , 2006, Annals of the New York Academy of Sciences.
[101] G. T. Budd,et al. Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival , 2006, Clinical Cancer Research.
[102] David Tollervey,et al. RNA-quality control by the exosome , 2006, Nature Reviews Molecular Cell Biology.
[103] M. Provencio,et al. Thymidylate Synthase Messenger RNA Expression in Plasma from Patients with Colon Cancer: Prognostic Potential , 2006, Clinical Cancer Research.
[104] M. Fukuda,et al. Clinical utility of quantitative RT‐PCR targeted to α1,4‐N‐acetylglucosaminyltransferase mRNA for detection of pancreatic cancer , 2006, Cancer science.
[105] Frank Diehl,et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[106] Jan Barciszewski,et al. A new frontier for molecular medicine: noncoding RNAs. , 2005, Biochimica et biophysica acta.
[107] H. Kalthoff,et al. Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival , 2005, Journal of Cancer Research and Clinical Oncology.
[108] Jian-guo Feng,et al. Detection of CK20mRNA in peripheral blood of pancreatic cancer and its clinical significance. , 2005, World journal of gastroenterology.
[109] Jonathan W. Uhr,et al. Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.
[110] Alison Stopeck,et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.
[111] R. Marchese,et al. Low value of detection of KRAS2 mutations in circulating DNA to differentiate chronic pancreatitis to pancreatic cancer , 2004, British Journal of Cancer.
[112] Y. Lo,et al. Quantification of plasma beta-catenin mRNA in colorectal cancer and adenoma patients. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.
[113] H. Friess,et al. Detection of circulating tumor cells by cytokeratin 20 and prostate stem cell antigen RT-PCR in blood of patients with gastrointestinal cancers. , 2003, Anticancer research.
[114] A. Lipton,et al. Epidermal growth factor receptor mRNA in peripheral blood of patients with pancreatic, lung, and colon carcinomas detected by RT-PCR. , 2003, International journal of oncology.
[115] N. Matsubara,et al. Allelic imbalance and microsatellite instability in plasma DNA released from polyclonal pancreatic adenocarcinoma. , 2002, International journal of oncology.
[116] P. Ruszniewski,et al. Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA , 2002, British Journal of Cancer.
[117] S. Natsugoe,et al. Intraoperative molecular detection of circulating tumor cells by reverse transcription-polymerase chain reaction in patients with biliary-pancreatic cancer is associated with hematogenous metastasis , 2002, Annals of Surgical Oncology.
[118] M. Provencio,et al. Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells , 2002, Gut.
[119] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[120] M. Provencio,et al. Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[121] J. Werner,et al. Biological implications of tumor cells in blood and bone marrow of pancreatic cancer patients. , 2001, Surgery.
[122] J. V. Moran,et al. Initial sequencing and analysis of the human genome. , 2001, Nature.
[123] M. Plebani,et al. ME-PCR for the identification of mutated K-ras in serum and bile of pancreatic cancer patients: an unsatisfactory technique for clinical applications. , 2000, Clinica chimica acta; international journal of clinical chemistry.
[124] H. Bonnefoi,et al. Telomerase RNA as a detection marker in the serum of breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[125] A. Figer,et al. Expression of cytokeratin 20 in the blood of patients with disseminated carcinoma of the pancreas, colon, stomach, and lung , 1999, Cancer.
[126] E. Friedman,et al. Detection of Pancreatic Carcinoma (Diagnostic Value of K-ras Mutations in Circulating DNA from Serum) , 1999, Digestive Diseases and Sciences.
[127] L. Kwak,et al. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[128] S. Leung,et al. Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. , 1999, Clinical chemistry.
[129] S. Natsugoe,et al. Molecular detection of circulating cancer cells during surgery in patients with biliary-pancreatic cancer. , 1999, American journal of surgery.
[130] G. Capellá,et al. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[131] K. Luzzi,et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. , 1998, The American journal of pathology.
[132] K. Iczkowski,et al. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. , 1998, Pancreas.
[133] M Monden,et al. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[134] M. Imamura,et al. Quantitative analysis of carcinoembryonic antigen messenger RNA in peripheral venous blood and portal blood of patients with pancreatic ductal adenocarcinoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[135] M. Imamura,et al. Identification of carcinoembryonic antigen mRNA in circulating peripheral blood of pancreatic carcinoma and gastric carcinoma patients. , 1996, Life sciences.
[136] Valeri Vasioukhin,et al. Point mutations of the N‐ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia , 1994, British journal of haematology.
[137] G. Fleuren,et al. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. , 1988, Nucleic acids research.
[138] D. Shibata,et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.
[139] D. Mccormick. Sequence the Human Genome , 1986, Bio/Technology.
[140] B. Shapiro,et al. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease , 1983, Cancer.
[141] B. Shapiro,et al. Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.
[142] J. Holland,et al. Elevated serum ribonuclease in patients with pancreatic cancer. , 1976, Proceedings of the National Academy of Sciences of the United States of America.
[143] I. Fidler,et al. Metastasis: Quantitative Analysis of Distribution and Fate of Tumor Emboli Labeled With 125I-5-Iodo-2′ -deoxyuridine , 1970 .
[144] P Mandel,et al. Les acides nucleiques du plasma sanguin chez l' homme , 1948 .
[145] Songbing He,et al. Effects of miR-16 plus CA19-9 detections on pancreatic cancer diagnostic performance. , 2014, Clinical laboratory.
[146] S. Lecleire,et al. Usefulness of Circulating Tumor Cell Detection in Pancreatic Adenocarcinoma Diagnosis , 2013, The American Journal of Gastroenterology.
[147] Peiyong Jiang,et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. , 2013, Clinical chemistry.
[148] Klaus Pantel,et al. Circulating tumor cells: liquid biopsy of cancer. , 2013, Clinical chemistry.
[149] Shadan Ali,et al. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. , 2010, American journal of translational research.
[150] K. Pantel,et al. Cancer micrometastases , 2009, Nature Reviews Clinical Oncology.
[151] 又木 雄弘. Carcinoembryonic antigen messenger RNA expression using nested reverse transcription-PCR in the peripheral blood during follow-up period of patients who underwent curative surgery for biliary-pancreatic cancer : Longitudinal analyses , 2004 .
[152] 内倉 敬一郎. Intraoperative molecular detection of circulating tumor cells by reverse transcription-polymerase chain reaction in patients with biliary-pancreatic cancer is associated with hematogenous metastasis , 2002 .
[153] International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome , 2001, Nature.
[154] V A Memoli,et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[155] N. Lemoine,et al. Ki-ras oncogene activation in preinvasive pancreatic cancer. , 1992, Gastroenterology.
[156] M. Omata,et al. Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma. , 1991, Gastroenterology.
[157] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.